Sur­rozen re­loads with $50M for fi­nal dash to the clin­ic, shines some light on lead Wnt-mod­u­lat­ing can­di­dates

Two rounds to­talling $83 mil­lion have pro­pelled Sur­rozen through pre­clin­i­cal proof-of-con­cept, cul­mi­nat­ing in two an­ti­body can­di­dates mod­u­lat­ing the Wnt path­way for tis­sue re­gen­er­a­tion. Now, the South San Fran­cis­co biotech is top­ping up $50 mil­lion to com­plete the sprint to the clin­ic.

One of the two IND can­di­dates tar­gets liv­er dis­ease while the oth­er will be ini­tial­ly po­si­tioned for in­flam­ma­to­ry bow­el dis­ease. With the cash in­fu­sion, Sur­rozen can al­so pur­sue more dis­cov­ery projects in dif­fer­ent tis­sues and ar­eas.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER